Enter your email address below and subscribe to our newsletter

Patient Education

Share your love

Glaukos Submits FDA Application for Epioxa Therapy

Glaukos Corporation has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its innovative corneal cross-linking therapy, Epioxa (Epi-on). This next-generation treatment is designed for patients with keratoconus and represents a significant advancement…

Stay informed and not overwhelmed, subscribe now!